Tumor necrosis factor alpha in sleep regulation

Sleep Medicine Reviews

Volumn 40, Issue , 2018, Pages 69-78

  Rockstrom, Matthew D ^a,b   Chen, Liangyu ^b,c   Taishi, Ping ^b   Nguyen, Joseph T ^b   Gibbons, Cody M ^a,b   Veasey, Sigrid C ^d   Krueger, James M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c CHINA MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoimmunity; Brain organization of sleep; Plasticity; Sleep function; Sleep regulation; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR;

BRAIN FUNCTION; BRAIN REGION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL MEMBRANE POTENTIAL; NERVE CELL PLASTICITY; NONHUMAN; NONREM SLEEP; PROTEIN EXPRESSION; PROTEIN FUNCTION; REM SLEEP; REVIEW; SIGNAL TRANSDUCTION; SLEEP PATTERN; SLEEP TIME; SYNAPTIC INHIBITION; ANIMAL; BLOOD; BRAIN; PHYSIOLOGY; SLEEP;

ANIMALS; BRAIN; HUMANS; NEURONAL PLASTICITY; SLEEP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85034448610     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2017.10.005     Document Type: Review

References (158)

1. Obal, F. Jr., Krueger, J.M., Humoral mechanisms of sleep. Parmeggiani, P.L., Velluti, R., (eds.) The physiological nature of sleep, 2005, Imperial College Press, London, 23–44.
2. Borbely, A.A., Processes underlying sleep regulation. Horm Res 49 (1998), 114–117.
3. Huang, Z.L., Urade, Y., Hayaishi, O., The role of adenosine in the regulation of sleep. Curr Top Med Chem 11 (2011), 1047–1057.
4. Huang, Z.L., Zhang, Z., Qu, W.M., Roles of adenosine and its receptors in sleep-wake regulation. Int Rev Neurobiol 119 (2014), 349–371.
5. Arias-Carrion, O., Huitron-Resendiz, S., Arankowsky-Sandoval, G., Murillo-Rodriguez, E., Biochemical modulation of the sleep-wake cycle: endogenous sleep-inducing factors. J Neurosci Res 89 (2011), 1143–1149.
6. Sheth, S., Brito, R., Mukherjea, D., Rybak, L.P., Ramkumar, V., Adenosine receptors: expression, function and regulation. Int J Mol Sci 15 (2014), 2024–2052.
7. Krueger, J.M., Huang, Y.H., Rector, D.M., Buysse, D.J., Sleep: a synchrony of cell activity-driven small network states. Eur J Neurosci 38 (2013), 2199–2209.
8. Krueger, J.M., Rector, D.M., Roy, S., Van Dongen, H.P.A., Belenky, G., Panksepp, J., Sleep as a fundamental property of neuronal assemblies. Nat Rev Neurosci 9 (2008), 910–919.
9. Krueger, J.M., Rector, D.M., Churchill, L., Sleep and cytokines. Sleep Med Clin 2 (2007), 161–169.
10. Luppi, P.H., Neurochemical aspects of sleep regulation with specific focus on slow-wave sleep. World J Biol Psychiatry 11:Suppl. 1 (2010), 4–8.
11. Szymusiak, R., McGinty, D., Hypothalamic regulation of sleep and arousal. Ann N Y Acad Sci 1129 (2008), 275–286.
12. Ingiosi, A.M., Opp, M.R., Krueger, J.M., Sleep and immune function: glial contributions and consequences of aging. Curr Opin Neurobiol 23 (2013), 806–811.
13. Frank, M.G., Astroglial regulation of sleep homeostasis. Curr Opin Neurobiol 23 (2013), 812–818.
14. Petit, J.M., Magistretti, P.J., Regulation of neuron-astrocyte metabolic coupling across the sleep-wake cycle. Neuroscience 323 (2016), 135–156.
15. O'Donnell, J., Ding, F., Nedergaard, M., Distinct functional states of astrocytes during sleep and wakefulness: is norepinephrine the master regulator?. Curr Sleep Med Rep 1 (2015), 1–8.
16. Santello, M., Bezzi, P., Volterra, A., TNFalpha controls glutamatergic gliotransmission in the hippocampal dentate gyrus. Neuron 69 (2011), 988–1001.
17. Guo, M., Lin, V., Davis, W., Huang, T., Carranza, A., Sprague, S., et al. Preischemic induction of TNF-alpha by physical exercise reduces blood-brain barrier dysfunction in stroke. J Cereb Blood Flow Metab 28 (2008), 1422–1430.
18. Turrigiano, G.G., The self-tuning neuron: synaptic scaling of excitatory synapses. Cell 135 (2008), 422–435.
19. Breder, C.D., Tsujimoto, M., Terano, Y., Scott, D.W., Saper, C.B., Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J Comp Neurol 337 (1993), 543–567.
20. Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y., Hirsch, E.C., Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 172 (1994), 151–154.
21. Cheng, B., Christakos, S., Mattson, M.P., Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 12 (1994), 139–153.
22. Botchkina, G.I., Meistrell, M.E. 3rd, Botchkina, I.L., Tracey, K.J., Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med 3 (1997), 765–781.
23. Shibata, M., Hypothalamic neuronal responses to cytokines. Yale J Biol Med 63 (1990), 147–156.
24. Saper, C.B., Breder, C.D., Endogenous pyrogens in the CNS: role in the febrile response. Prog Brain Res 93 (1992), 419–428.
25. Plata-Salaman, C.R., Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 16 (2000), 1009–1012.
26. Yirmiya, R., Goshen, I., Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 25 (2011), 181–213.
27. Merrill, J.E., Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 14 (1992), 1–10.
28. McCoy, M.K., Tansey, M.G., TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflamm, 5, 2008, 45, 10.1186/1742-2094-5-45.
29. O'Connor, J.J., Targeting tumour necrosis factor-alpha in hypoxia and synaptic signalling. Ir J Med Sci 182 (2013), 157–162.
30. Horiuchi, T., Mitoma, H., Harashima, S., Tsukamoto, H., Shimoda, T., Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology 49 (2010), 1215–1228.
31. Kriegler, M., Perez, C., DeFay, K., Albert, I., Lu, S.D., A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53 (1988), 45–53.
32. Ledgerwood, E.C., Pober, J.S., Bradley, J.R., Recent advances in the molecular basis of TNF signal transduction. Lab Invest 79 (1999), 1041–1050.
33. Goeddel, D.V., Signal transduction by tumor necrosis factor: the Parker B. Francis Lectureship. Chest 116 (1999), 69S–73S.
34. Kyriakis, J.M., Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family. Gene Expr 7 (1999), 217–231.
35. Wallach, D., Varfolomeev, E.E., Malinin, N.L., Goltsev, Y.V., Kovalenko, A.V., Boldin, M.P., Tumor necrosis factor receptor and Fas signaling mechanisms. Ann Rev Immunol 17 (1999), 331–367.
36. Inoue, J., Ishida, T., Tsukamoto, N., Kobayashi, N., Naito, A., Azuma, S., et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 254 (2000), 14–24.
37. Churchill, L., Rector, D.M., Yasuda, K., Fix, C., Rojas, M.J., Yasuda, T., et al. Tumor necrosis factor alpha: activity dependent expression and promotion of cortical column sleep in rats. Neuroscience 156 (2008), 71–80.
38. Borst, S.E., Conover, C.F., High-fat diet induces increased tissue expression of TNF-alpha. Life Sci 77 (2005), 2156–2165.
39. Spriggs, D.R., Deutsch, S., Kufe, D.W., Genomic structure, induction, and production of TNF-alpha. Immunol Ser 56 (1992), 3–34.
40. Kisiswa, L., Osorio, C., Erice, C., Vizard, T., Wyatt, S., Davies, A.M., TNFalpha reverse signaling promotes sympathetic axon growth and target innervation. Nat Neurosci 16 (2013), 865–873.
41. Kohchi, C., Tanabe, Y., Noguchi, K., Mizuno, D., Soma, G., Induction of differentiation in embryonic stem cells by 26-kD membrane-bound tumor necrosis factor (TNF) and 17-kD free TNF. In Vivo 10 (1996), 19–27.
42. Jewett, K.A., Taishi, P., Sengupta, P., Roy, S., Davis, C.J., Krueger, J.M., Tumor necrosis factor enhances the sleep-like state and electrical stimulation induces a wake-like state in co-cultures of neurons and glia. Eur J Neurosci 42 (2015), 2078–2090.
43. Beattie, E.C., Stellwagen, D., Morishita, W., Bresnahan, J.C., Ha, B.K., Von Zastrow, M., et al. Control of synaptic strength by glial TNFalpha. Science 295 (2002), 2282–2285.
44. De, A., Krueger, J.M., Simasko, S.M., Tumor necrosis factor alpha increases cytosolic calcium responses to AMPA and KCl in primary cultures of rat hippocampal neurons. Brain Res 981 (2003), 133–142.
45. Furukawa, K., Mattson, M.P., The transcription factor NF-kappaB mediates increases in calcium currents and decreases in NMDA- and AMPA/kainate-induced currents induced by tumor necrosis factor-alpha in hippocampal neurons. J Neurochem 70 (1998), 1876–1886.
46. Stellwagen, D., Malenka, R.C., Synaptic scaling mediated by glial TNF-alpha. Nature 440 (2006), 1054–1059.
47. Karrer, M., Lopez, M.A., Meier, D., Mikhail, C., Ogunshola, O.O., Muller, A.F., et al. Cytokine-induced sleep: neurons respond to TNF with production of chemokines and increased expression of Homer1a in vitro. Brain Behav Immun 47 (2015), 186–192.
48. Nelson, S.E., Duricka, D.L., Campbell, K., Churchill, L., Krueger, J.M., Homer1a and 1bc levels in the rat somatosensory cortex vary with the time of day and sleep loss. Neurosci Lett 367 (2004), 105–108.
49. Maret, S., Dorsaz, S., Gurcel, L., Pradervand, S., Petit, B., Pfister, C., et al. Homer1a is a core brain molecular correlate of sleep loss. Proc Natl Acad Sci U S A 104 (2007), 20090–20095.
50. Borbely, A.A., Tobler, I., Endogenous sleep-promoting substances and sleep regulation. Physiol Rev 69 (1989), 605–670.
51. Inoué, S., Biology of sleep substances. 1989, CRC Press.
52. Krueger, J.M., Fang, J., Taishi, P., Chen, Z., Kushikata, T., Gardi, J., Sleep. A physiologic role for IL-1 beta and TNF-alpha. Ann N Y Acad Sci 856 (1998), 148–159.
53. Shoham, S., Davenne, D., Cady, A.B., Dinarello, C.A., Krueger, J.M., Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. Am J Physiol 253 (1987), R142–R149.
54. Nistico, G., DeSarro, G., Rotiroti, D., Behavioral and electrocortical spectrum power changes of interleukins and tumor necrosis factor after microinjection into different areas of the brain. Smirne, S., Franceschi, M., Ferini-Strambi, Zucconi, M., (eds.) Sleep, hormones and immunological system, 1992, Masson, 11–22.
55. Fang, J., Wang, Y., Krueger, J.M., Mice lacking the TNF 55 kDa receptor fail to sleep more after TNFalpha treatment. J Neurosci 17 (1997), 5949–5955.
56. Dickstein, J.B., Moldofsky, H., Lue, F.A., Hay, J.B., Intracerebroventricular injection of TNF-alpha promotes sleep and is recovered in cervical lymph. Am J Physiol 276 (1999), R1018–R1022.
57. Davis, C.J., Clinton, J.M., Jewett, K.A., Zielinski, M.R., Krueger, J.M., Delta wave power: an independent sleep phenotype or epiphenomenon?. J Clin Sleep Med 7 (2011), S16–S18.
58. Terao, A., Matsumura, H., Yoneda, H., Saito, M., Enhancement of slow-wave sleep by tumor necrosis factor-alpha is mediated by cyclooxygenase-2 in rats. Neuroreport 9 (1998), 3791–3796.
59. Takahashi, S., Kapas, L., Fang, J., Krueger, J.M., An anti-tumor necrosis factor antibody suppresses sleep in rats and rabbits. Brain Res 690 (1995), 241–244.
60. Takahashi, S., Tooley, D.D., Kapas, L., Fang, J., Seyer, J.M., Krueger, J.M., Inhibition of tumor necrosis factor in the brain suppresses rabbit sleep. Pflugers Arch Eur J Physiol 431 (1995), 155–160.
61. Takahashi, S., Krueger, J.M., Inhibition of tumor necrosis factor prevents warming-induced sleep responses in rabbits. Am J Physiol 272 (1997), R1325–R1329.
62. Takahashi, S., Kapas, L., Seyer, J.M., Wang, Y., Krueger, J.M., Inhibition of tumor necrosis factor attenuates physiological sleep in rabbits. Neuroreport 7 (1996), 642–646.
63. Kapas, L., Bohnet, S.G., Traynor, T.R., Majde, J.A., Szentirmai, E., Magrath, P., et al. Spontaneous and influenza virus-induced sleep are altered in TNF-alpha double-receptor deficient mice. J Appl Physiol 105 (2008), 1187–1198.
64. Floyd, R.A., Krueger, J.M., Diurnal variation of TNF alpha in the rat brain. Neuroreport 8 (1997), 915–918.
65. Bredow, S., Guha-Thakurta, N., Taishi, P., Obal, F. Jr., Krueger, J.M., Diurnal variations of tumor necrosis factor alpha mRNA and alpha-tubulin mRNA in rat brain. Neuroimmunomodulation 4 (1997), 84–90.
66. Veasey, S., Mackiewicz, M., Fenik, P., Ro, M., Oglivie, M., Pack, A., IL1 beta knockout mice lack the TNF alpha response to sleep deprivation but have normal sleep and sleep recovery. Soc Neurosci Abst, 23, 1997, 792.
67. Taishi, P., Gardi, J., Chen, Z., Fang, J., Krueger, J., Sleep deprivation increases the expression of TNF alpha mRNA and TNF 55 kD receptor mRNA in rat brain. Physiologist, 42, 1999, A4.
68. Venancio, D.P., Suchecki, D., Prolonged REM sleep restriction induces metabolic syndrome-related changes: mediation by pro-inflammatory cytokines. Brain Behav Immun 47 (2015), 109–117.
69. Chennaoui, M., Gomez-Merino, D., Drogou, C., Geoffroy, H., Dispersyn, G., Langrume, C., et al. Effects of exercise on brain and peripheral inflammatory biomarkers induced by total sleep deprivation in rats. J Inflamm, 12, 2015, 56.
70. Ramesh, V., Nair, D., Zhang, S.X., Hakim, F., Kaushal, N., Kayali, F., et al. Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-α pathway. J Neuroinflamm, 9, 2012, 91.
71. Ashley, N.T., Sams, D.W., Brown, A.C., Dumaine, J.E., Novel environment influences the effect of paradoxical sleep deprivation upon brain and peripheral cytokine gene expression. Neurosci Lett 615 (2016), 55–59.
72. Cathomas, F., Fuertig, R., Sigrist, H., Newman, G.N., Hoop, V., Bizzozzero, M., et al. CD40-TNF activation in mice induces extended sickness behavior syndrome co-incident with but not dependent on activation of the kynurenine pathway. Brain Behav Immun 50 (2015), 125–140.
73. Zielinski, M.R., Dunbrasky, D.L., Taishi, P., Souza, G., Krueger, J.M., Vagotomy attenuates brain cytokines and sleep induced by peripherally administered tumor necrosis factor-alpha and lipopolysaccharide in mice. Sleep 36 (2013), 1227–1238.
74. Kubota, T., Li, N., Guan, Z., Brown, R.A., Krueger, J.M., Intrapreoptic microinjection of TNF-α enhances non-REM sleep in rats. Brain Res 932 (2002), 37–44.
75. De Sarro, G., Gareri, P., Sinopoli, V.A., David, E., Rotiroti, D., Comparative, behavioural and electrocortical effects of tumor necrosis factor-α and interleukin-1 microinjected into the locus coeruleus of rat. Life Sci 60 (1997), 555–564.
76. Rector, D.M., Schei, J.L., Van Dongen, H., Belenky, G., Krueger, J.M., Physiological markers of local sleep. Eur J Neurosci 29 (2009), 1771–1778.
77. Yoshida, H., Peterfi, Z., Garcı́a-Garcı́a, F., Kirkpatrick, R., Yasuda, T., Krueger, J.M., State-specific asymmetries in EEG slow wave activity induced by local application of TNFα. Brain Res 1009 (2004), 129–136.
78. Taishi, P., Churchill, L., Wang, M., Kay, D., Davis, C.J., Guan, X., et al. TNFα siRNA reduces brain TNF and EEG delta wave activity in rats. Brain Res 1156 (2007), 125–132.
79. Darko, D.F., Miller, J.C., Gallen, C., White, J., Koziol, J., Brown, S.J., et al. Sleep electroencephalogram delta-frequency amplitude, night plasma levels of tumor necrosis factor alpha, and human immunodeficiency virus infection. Proc Nat Acad Sci U S A 92 (1995), 12080–12084.
80. Dimitrov, S., Besedovsky, L., Born, J., Lange, T., Differential acute effects of sleep on spontaneous and stimulated production of tumor necrosis factor in men. Brain Behav Immun 47 (2015), 201–210.
81. Shearer, W.T., Reuben, J.M., Mullington, J.M., Price, N.J., Lee, B.N., Smith, E.O., et al. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol 107 (2001), 165–170.
82. Haack, M., Pollmacher, T., Mullington, J.M., Diurnal and sleep-wake dependent variations of soluble TNF- and IL-2 receptors in healthy volunteers. Brain Behav Immun 18 (2004), 361–367.
83. Puccioni-Sohler, M., Rieckmann, P., Kitze, B., Lange, P., Albrecht, M., Felgenhauer, K., A soluble form of tumour necrosis factor receptor in cerebrospinal fluid and serum of HTLV-I-associated myelopathy and other neurological diseases. J Neurol 242 (1995), 239–242.
84. Mullington, J., Korth, C., Hermann, D.M., Orth, A., Galanos, C., Holsboer, F., et al. Dose-dependent effects of endotoxin on human sleep. Am J Physiol 278 (2000), R947–R955.
85. Eskander, E.D., Harvey, H.A., Givant, E., Lipton, A., Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2. Am J Clin Oncol 20 (1997), 511–514.
86. Raudonis, B.M., Kelley, I.H., Rowe, N., Ellis, J., A pilot study of proinflammatory cytokines and fatigue in women with breast cancer during chemotherapy. Cancer Nurs 40 (2017), 323–331.
87. Gozal, D., Serpero, L.D., Kheirandish-Gozal, L., Capdevila, O.S., Khalyfa, A., Tauman, R., Sleep measures and morning plasma TNF-alpha levels in children with sleep-disordered breathing. Sleep 33 (2010), 319–325.
88. Khalyfa, A., Serpero, L.D., Kheirandish-Gozal, L., Capdevila, O.S., Gozal, D., TNF-α gene polymorphisms and excessive daytime sleepiness in pediatric obstructive sleep apnea. J Pediatr 158 (2011), 77–82.
89. Bielicki, P., MacLeod, A.K., Douglas, N.J., Riha, R.L., Cytokine gene polymorphisms inobstructive sleep apnoea/hypopnoea syndrome. Sleep Med 16 (2015), 792–795.
90. Zhong, A., Xiong, X., Xu, H., Shi, M., An updated meta-analysis of the association between tumor necrosis factor-α-308G/A polymorphism and obstructive sleep apnea-hypopnea syndrome. PLoS One, 9(9), 2014 Sep 15, e106270.
91. Wu, Y., Cao, C., Wu, Y., Zhang, C., Zhu, C., Ying, S., et al. TNF-α-308G/A polymorphism contributes to obstructive sleep apnea syndrome risk: evidence based on 10 case-control studies. PLoS One, 9(9), 2014 Sep 5, e106183.
92. Almpanidou, P., Hadjigeorgiou, G., Gourgoulianis, K., Papadimitriou, A., Association of tumor necrosis factor-α gene polymorphism (-308) and obstructive sleepapnea-hypopnea syndrome. Hippokratia 16:3 (2012 Jul), 217–220.
93. Davis, C.J., Krueger, J.M., Sleep and cytokines. Sleep Med Clin 7 (2012), 517–527.
94. Ceylan, E., Karkucak, M., Coban, H., Karadag, M., Yakut, T., Evaluation of TNF-alpha gene (G308A) and MBL2 gene codon 54 polymorphisms in Turkish patients with tuberculosis. J Infect Public Health 10 (2017), 774–777.
95. Wang, T., TNF-alpha G308A polymorphism and the susceptibility to Alzheimer's disease: an updated meta-analysis. Arch Med Res, 46, 2015 24–30 e1.
96. Oliveira, J.B., Silva, P.C., Vasconcelos, L.M., Gomes, A.V., Coelho, M.R., Cahu, G.G., et al. Influence of polymorphism (-G308A) TNF-alpha on the periportal fibrosis regression of schistosomiasis after specific treatment. Genet Test Mol Biomark 19 (2015), 598–603.
97. Satterfield, B.C., Wisor, J.P., Field, S.A., Schmidt, M.A., Van Dongen, H.P., TNFalpha G308A polymorphism is associated with resilience to sleep deprivation-induced psychomotor vigilance performance impairment in healthy young adults. Brain Behav Immun 47 (2015), 66–74.
98. Opp, M.R., George, A., Ringgold, K.M., Hansen, K.M., Bullock, K.M., Banks, W.A., Sleep fragmentation and sepsis differentially impact blood–brain barrier integrity and transport of tumor necrosis factor-α in aging. Brain Behav Immun 50 (2015), 259–265.
99. De Muynck, L., Van Damme, P., Cellular effects of progranulin in health and disease. J Mol Neurosci 45 (2011), 549–560.
100. Jian, J., Li, G., Hettinghouse, A., Liu, C., Progranulin: a key player in autoimmune diseases. Cytokine, 2016, 10.1016/j.cyto.2016.08.007 (in press).
101. Zhang, K., Li, Y.J., Feng, D., Zhang, P., Wang, Y.T., Li, X., et al. Imbalance between TNFalpha and progranulin contributes to memory impairment and anxiety in sleep-deprived mice. Sci Rep, 7, 2017, 43594.
102. Zalevsky, J., Secher, T., Ezhevsky, S.A., Janot, L., Steed, P.M., O'Brien, C., et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179 (2007), 1872–1883.
103. Crunkhorn, S., Autoimmune diseases: new route to targeting TNF. Nat Rev Drug Discov, 10, 2011, 337.
104. Mease, P.J., Goffe, B.S., Metz, J., VanderStoep, A., Finck, B., Burge, D.J., Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000), 385–390.
105. Detert, J., Dziurla, R., Hoff, P., Gaber, T., Klaus, P., Bastian, H., et al. Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis. Clin Exp Rheumatol 34 (2016), 848–856.
106. Wolfe, F., Michaud, K., Li, T., Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol 33 (2006), 1942–1951.
107. Pavelka, K., Szekanecz, Z., Damjanov, N., Majdan, M., Nasonov, E., Mazurov, V., et al. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clin Rheumatol 32 (2013), 1275–1281.
108. Thaci, D., Galimberti, R., Amaya-Guerra, M., Rosenbach, T., Robertson, D., Pedersen, R., et al. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. J Eur Acad Dermatol Venereol 28 (2014), 900–906.
109. Karadag, O., Nakas, D., Kalyoncu, U., Akdogan, A., Kiraz, S., Ertenli, I., Effect of anti-TNF treatment on sleep problems in ankylosing spondylitis. Rheumatol Int 32 (2012), 1909–1913.
110. Vgontzas, A.N., Zoumakis, E., Lin, H.M., Bixler, E.O., Trakada, G., Chrousos, G.P., Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab 89 (2004), 4409–4413.
111. Irwin, M.R., Olmstead, R., Valladares, E.M., Breen, E.C., Ehlers, C.L., Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence. Biol Psychiatry 66 (2009), 191–195.
112. Burness, C.B., McKeage, K., Adalimumab: a review in chronic plaque psoriasis. Drugs 75 (2015), 2119–2130.
113. Pecoraro, V., De Santis, E., Melegari, A., Trenti, T., The impact of immunogenicity of TNFalpha inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. Autoimmun Rev 16 (2017), 564–575.
114. Emara, M.K., Saadah, A., Hassan, M., Moussa, M., Hourani, H., Pattern of obesity and insulin, glucagon, sex hormone binding globulin and lipids in obese Arab women. Diabetes Res 10 (1989), 175–181.
115. Strober, B.E., Sobell, J.M., Duffin, K.C., Bao, Y., Guerin, A., Yang, H., et al. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol 167 (2012), 1374–1381.
116. Ward, M.M., Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12 (1999), 247–255.
117. Rudwaleit, M., Gooch, K., Michel, B., Herold, M., Thorner, A., Wong, R., et al. Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis. J Rheumatol 38 (2011), 79–86.
118. Acosta-Felquer, M.L., Rosa, J., Soriano, E.R., An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatol Res Rev 8 (2016), 37–44.
119. Cauli, A., Piga, M., Lubrano, E., Marchesoni, A., Floris, A., Mathieu, A., New approaches in tumor necrosis factor antagonism for the treatment of psoriatic arthritis: certolizumab Pegol. J Rheumatol Suppl 93 (2015), 70–72.
120. Sieper, J., Kivitz, A., van Tubergen, A., Deodhar, A., Coteur, G., Woltering, F., et al. Impact of Certolizumab Pegol on patient-reported outcomes in patients with axial spondyloarthritis. Arthritis Care Res 67 (2015), 1475–1480.
121. Harzallah, I., Rigaill, J., Williet, N., Paul, S., Roblin, X., Golimumab pharmacokinetics in ulcerative colitis: a literature review. Therap Adv Gastroenterol 10 (2017), 89–100.
122. Bao, C., Huang, F., Khan, M.A., Fei, K., Wu, Z., Han, C., et al. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology 53 (2014), 1654–1663.
123. Inman, R.D., Davis, J.C. Jr., Heijde, D., Diekman, L., Sieper, J., Kim, S.I., et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58 (2008), 3402–3412.
124. Huerva, V., Ascaso, F.J., Grzybowski, A., Infliximab for peripheral ulcerative keratitis treatment. Medicine, 93, 2014, e176.
125. Vaz, J.L., Fernandes, V., Nogueira, F., Arnobio, A., Levy, R.A., Infliximab-induced autoantibodies: a multicenter study. Clin Rheumatol 35 (2016), 325–332.
126. Zamarron, C., Maceiras, F., Mera, A., Gomez-Reino, J.J., Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis 63 (2004), 88–90.
127. Majumder, S., Sreedhara, S.R., Banerjee, S., Chatterjee, S., TNF alpha signaling beholds thalidomide saga: a review of mechanistic role of TNF-alpha signaling under thalidomide. Curr Top Med Chem 12 (2012), 1456–1467.
128. Bramuzzo, M., Ventura, A., Martelossi, S., Lazzerini, M., Thalidomide for inflammatory bowel disease: systematic review. Medicine, 95, 2016, e4239.
129. Wang, D., Chen, H., Wang, S., Zou, Y., Li, J., Pan, J., et al. Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China. Clin Rheumatol 35 (2016), 1521–1527.
130. Lateef, A., Petri, M., Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 22 (2010), 504–509.
131. Hassler, M.R., Sax, C., Flechl, B., Ackerl, M., Preusser, M., Hainfellner, J.A., et al. Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. Oncology 88 (2015), 173–179.
132. Albulescu, R., Codrici, E., Popescu, I.D., Mihai, S., Necula, L.G., Petrescu, D., et al. Cytokine patterns in brain tumour progression. Mediat Inflamm, 2013, 2013, 979748.
133. Fox, M.R., Harris, A., Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology 120 (2001), 1567–1568.
134. Mujagic, H., Chabner, B.A., Mujagic, Z., Mechanisms of action and potential therapeutic uses of thalidomide. Croat Med J 43 (2002), 274–285.
135. Dimopoulos, M.A., Eleutherakis-Papaiakovou, V., Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117 (2004), 508–515.
136. Kanbayashi, T., Shimizu, T., Takahashi, Y., Kitajima, T., Takahashi, K., Saito, Y., et al. Thalidomide increases both REM and stage 3–4 sleep in human adults: a preliminary study. Sleep 22 (1999), 113–115.
137. Brietzke, E., Kapczinski, F., TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008), 1355–1361.
138. Barbosa, I.G., Rocha, N.P., Huguet, R.B., Ferreira, R.A., Salgado, J.V., Carvalho, L.A., et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord 137 (2012), 151–155.
139. Ribeiro-Santos, A., Lucio Teixeira, A., Salgado, J.V., Evidence for an immune role on cognition in schizophrenia: a systematic review. Curr Neuropharmacol 12 (2014), 273–280.
140. Bortolato, B., Carvalho, A.F., Soczynska, J.K., Perini, G.I., McIntyre, R.S., The Involvement of TNF-alpha in cognitive dysfunction associated with major depressive disorder: an opportunity for domain specific treatments. Curr Neuropharmacol 13 (2015), 558–576.
141. Shoham, S., Blatteis, C.M., Krueger, J.M., Effects of preoptic area lesions on muramyl dipeptide-induced sleep and fever. Brain Res 476 (1989), 396–399.
142. Edgar, D.M., Dement, W.C., Fuller, C.A., Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J Neurosci 13 (1993), 1065–1079.
143. Mendelson, W.B., Bergmann, B.M., Tung, A., Baseline and post-deprivation recovery sleep in SCN-lesioned rats. Brain Res 980 (2003), 185–190.
144. Mukhametov, L.M., Unihemispheric slow-wave sleep in the Amazonian dolphin, Inia geoffrensis. Neurosci Lett 79 (1987), 128–132.
145. Rattenborg, N.C., Lima, S.L., Lesku, J.A., Sleep locally, act globally. Neuroscience 18 (2012), 533–546.
146. Mascetti, G.G., Unihemispheric sleep and asymmetrical sleep: behavioral, neurophysiological, and functional perspectives. Nat Sci Sleep 8 (2016), 221–238.
147. Mahowald, M.W., Cramer Bornemann, M.A., Schenck, C.H., State dissociation, human behavior, and consciousness. Curr Top Med Chem 11 (2011), 2392–2402.
148. Krueger, J.M., Obal, F., A neuronal group theory of sleep function. J Sleep Res 2 (1993), 63–69.
149. Rector, D.M., Topchiy, I.A., Carter, K.M., Rojas, M.J., Local functional state differences between rat cortical columns. Brain Res 1047 (2005), 45–55.
150. Corner, M.A., Reciprocal homeostatic responses to excitatory synaptic receptor inactivation in developing organotypic cortical networks in vitro. Neurosci Lett 438 (2008), 300–302.
151. Hinard, V., Mikhail, C., Pradervand, S., Curie, T., Houtkooper, R.H., Auwerx, J., et al. Key electrophysiological, molecular, and metabolic signatures of sleep and wakefulness revealed in primary cortical cultures. J Neurosci 32 (2012), 12506–12517.
152. Frank, M.G., Sleep and plasticity in the visual cortex: more than meets the eye. Curr Opin Neurobiol 44 (2017), 8–12.
153. Tononi, G., Cirelli, C., Some considerations on sleep and neural plasticity. Arch Ital Biol 139 (2001), 221–241.
154. Tononi, G., Cirelli, C., Sleep function and synaptic homeostasis. Sleep Med Rev 10 (2006), 49–62.
155. Krueger, J.M., Frank, M.G., Wisor, J.P., Roy, S., Sleep function: toward elucidating an enigma. Sleep Med Rev 28 (2016), 46–54.
156. Crick, F., Mitchison, G., REM sleep and neural nets. Behav Brain Res 69 (1995), 147–155.
157. Kavanau, J.L., Sleep and dynamic stabilization of neural circuitry: a review and synthesis. Behav Brain Res 63 (1994), 111–126.
158. Krueger, J.M., Roy, S., Sleep's Kernel: surprisingly small sections of brain, and even neuronal and glial networks in a dish, display many electrical indicators of sleep. Scientist 30 (2016), 36–41.